Sambuddha Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sambuddha Kumar has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Govind K. Makharia
Department of Gastroenterology and Human Nutrition All India Institute of Medical Sciences New Delhi India
2 shared publications - Vineet Ahuja
Department of Gastroenterology All India Institute of Medical Sciences New Delhi India
2 shared publications Aditya Vikram Pachisia
Department of Gastroenterology, Command Hospital (AF), Bangalore, India
1 shared publicationAlka Kumari
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India
1 shared publicationAnand Krishnan
Affiliation Center for Community Medicine, All India Institute of Medical Sciences, New Delhi, India
1 shared publication- Ankit Agarwal
All India Institute of Medical Sciences
1 shared publication
Latest Publications
- 26 November 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2113-2124
Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet
INTRODUCTION: Liver involvement is common in celiac disease (CeD), and up to 4.6% of patients with cryptogenic cirrhosis have CeD. We investigated the prevalence of CeD in patients with cryptogenic cirrhosis and assessed liver-related outcomes in them on GFD when compared with a propensity score–matched cohort of patients with cryptogenic cirrhosis without CeD. METHODS: Consecutive patients with cryptogenic cirrhosis were screened for CeD using IgA anti–tissue transglutaminase antibody (anti-tTG) followed by antiendomysial antibody and duodenal and liver biopsies, on which IgA/anti-tTG colocalization studies were performed. These patients and a cohort of patients with cryptogenic cirrhosis without CeD (1:4 CeD: no CeD matched using propensity score matched for age, sex, Child–Turcotte–Pugh [CTP] and model for end-stage liver disease [MELD]) were initiated on GFD plus standard of care and standard of care, respectively, and followed up for liver-related outcomes for 1 year. RESULTS: Of 232 patients with cryptogenic cirrhosis, 14 had high anti-tTG Ab (16.9 ± 10.5 fold rise), with 9 antiendomysial antibody–positive and 11 (4.7%) biopsy-proven CeD. IgA/anti-tTG Ab colocalization was demonstrated in 7/8 liver and 10/11 duodenal biopsies. Patients with cryptogenic cirrhosis with definite CeD (n = 11) and matched cohort without CeD (n = 44) were similar at baseline (age: 31.3 ± 7.7 vs 31.8 ± 9.3 years; 5 [45.5%] vs 15 [34.1%] females; MELDNa 9 [interquartile-range: 8–15.5] vs 12 [9–15]; CTP 7 [6–7.5] vs 6 [5.75–7]). Patients with CeD on GFD improved significantly on follow-up compared with those without CeD (follow-up MELDNa: 9 [7.5–10.5] vs 18.5 [12-20]; P = 0.001 and follow-up CTP: 5 [5-5] vs 8 [7–9]; P < 0.001) with less frequent further decompensations and similar mortality (9.1% vs 18.2%; P = 0.67). DISCUSSION: Approximately 4.7% of patients with cryptogenic cirrhosis have biopsy-proven CeD, and their liver-related outcomes improve with GFD.
- 26 November 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2113-2124
Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet
INTRODUCTION: Liver involvement is common in celiac disease (CeD), and up to 4.6% of patients with cryptogenic cirrhosis have CeD. We investigated the prevalence of CeD in patients with cryptogenic cirrhosis and assessed liver-related outcomes in them on GFD when compared with a propensity score–matched cohort of patients with cryptogenic cirrhosis without CeD. METHODS: Consecutive patients with cryptogenic cirrhosis were screened for CeD using IgA anti–tissue transglutaminase antibody (anti-tTG) followed by antiendomysial antibody and duodenal and liver biopsies, on which IgA/anti-tTG colocalization studies were performed. These patients and a cohort of patients with cryptogenic cirrhosis without CeD (1:4 CeD: no CeD matched using propensity score matched for age, sex, Child–Turcotte–Pugh [CTP] and model for end-stage liver disease [MELD]) were initiated on GFD plus standard of care and standard of care, respectively, and followed up for liver-related outcomes for 1 year. RESULTS: Of 232 patients with cryptogenic cirrhosis, 14 had high anti-tTG Ab (16.9 ± 10.5 fold rise), with 9 antiendomysial antibody–positive and 11 (4.7%) biopsy-proven CeD. IgA/anti-tTG Ab colocalization was demonstrated in 7/8 liver and 10/11 duodenal biopsies. Patients with cryptogenic cirrhosis with definite CeD (n = 11) and matched cohort without CeD (n = 44) were similar at baseline (age: 31.3 ± 7.7 vs 31.8 ± 9.3 years; 5 [45.5%] vs 15 [34.1%] females; MELDNa 9 [interquartile-range: 8–15.5] vs 12 [9–15]; CTP 7 [6–7.5] vs 6 [5.75–7]). Patients with CeD on GFD improved significantly on follow-up compared with those without CeD (follow-up MELDNa: 9 [7.5–10.5] vs 18.5 [12-20]; P = 0.001 and follow-up CTP: 5 [5-5] vs 8 [7–9]; P < 0.001) with less frequent further decompensations and similar mortality (9.1% vs 18.2%; P = 0.67). DISCUSSION: Approximately 4.7% of patients with cryptogenic cirrhosis have biopsy-proven CeD, and their liver-related outcomes improve with GFD.
- Open Access
- 30 April 2022
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 20 (2) , 269-273
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
- 30 April 2022
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 20 (2) , 269-273
Open AccessCorrelation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
- Open Access
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246522
Carriage rates and antimicrobial sensitivity of pneumococci in the upper respiratory tract of children less than ten years old, in a north Indian rural community
Pneumococcal carriage studies are important for vaccine introduction and treatment strategies. Pneumococcal carriage rates estimated in this cohort study among children in a rural community of northern India. Between August 2012 and August 2014, trained nurses made weekly home visits to screen enrolled children aged <10 years for acute upper or lower respiratory infections (AURI/ALRI) in Ballabgarh, Haryana. Nasal swab from infants aged <1year and throat swab from children aged ≥1 year were collected. All specimens were cultured for pneumococci; isolates were serotyped and subjected to antimicrobial susceptibility testing. During the study period, 4348 nasal/throat swabs collected from children with clinical features of ARI (836 ALRI, 2492 AURI) and from 1020 asymptomatic children. Overall pneumococcal carriage was 5.1%, the highest carriage rate among children <1 year of age (22.6%). The detection rates were higher among children with ARI (5.6%; 95% CI: 4.8–6.4) than asymptomatic children (3.3%; 95% CI: 2.3–4.6). Among 220 pneumococcal isolates, 42 diverse serotypes were identified, with 6B/C (8.6%), 19A (7.2%), 19F (6.8%), 23F (6.4%), 35A/B/C (6.4%), 15B (5%), 14 (4.5%) and 11A/C/D (3.2%) accounting for 50%. Forty-five percent of the serotypes identified are included in the current formulation of 13-valent pneumococcal conjugate vaccine. Ninety-six percent of isolates were resistant to co-trimoxazole, 9% were resistant to erythromycin, and 10% had intermediate resistance to penicillin with minimum inhibitory concentration ranges (0.125 to 1.5 μg/ml). Pneumococcal detection was relatively low among children in our study community but demonstrated a diverse range of serotypes and half of these serotypes would be covered by the current formulation of 13-valent pneumococcal vaccine.
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246522
Open AccessCarriage rates and antimicrobial sensitivity of pneumococci in the upper respiratory tract of children less than ten years old, in a north Indian rural community
Pneumococcal carriage studies are important for vaccine introduction and treatment strategies. Pneumococcal carriage rates estimated in this cohort study among children in a rural community of northern India. Between August 2012 and August 2014, trained nurses made weekly home visits to screen enrolled children aged <10 years for acute upper or lower respiratory infections (AURI/ALRI) in Ballabgarh, Haryana. Nasal swab from infants aged <1year and throat swab from children aged ≥1 year were collected. All specimens were cultured for pneumococci; isolates were serotyped and subjected to antimicrobial susceptibility testing. During the study period, 4348 nasal/throat swabs collected from children with clinical features of ARI (836 ALRI, 2492 AURI) and from 1020 asymptomatic children. Overall pneumococcal carriage was 5.1%, the highest carriage rate among children <1 year of age (22.6%). The detection rates were higher among children with ARI (5.6%; 95% CI: 4.8–6.4) than asymptomatic children (3.3%; 95% CI: 2.3–4.6). Among 220 pneumococcal isolates, 42 diverse serotypes were identified, with 6B/C (8.6%), 19A (7.2%), 19F (6.8%), 23F (6.4%), 35A/B/C (6.4%), 15B (5%), 14 (4.5%) and 11A/C/D (3.2%) accounting for 50%. Forty-five percent of the serotypes identified are included in the current formulation of 13-valent pneumococcal conjugate vaccine. Ninety-six percent of isolates were resistant to co-trimoxazole, 9% were resistant to erythromycin, and 10% had intermediate resistance to penicillin with minimum inhibitory concentration ranges (0.125 to 1.5 μg/ml). Pneumococcal detection was relatively low among children in our study community but demonstrated a diverse range of serotypes and half of these serotypes would be covered by the current formulation of 13-valent pneumococcal vaccine.